Under-Eye Dark Circles Treatment

“Dark circles” is one of the least precise treatment requests in aesthetic medicine.

Two patients can look in the mirror and describe exactly the same thing — “I always look tired” — while the reason for the darkness beneath their eyes is completely different.

In one patient, the skin itself contains increased pigment. In another, the skin is so thin that underlying vascular and muscular colour shows through. Another patient has almost no true discoloration at all; a tear-trough depression casts a shadow that disappears when the lighting changes. Lower-eyelid bags can create another shadow below their own projection. Fluid retention can make the contour change from morning to evening.

Most patients are not one pure type.

This is why I do not think “under-eye treatment” should begin with filler, mesotherapy, laser or an eye cream.

It begins with optics and anatomy: is what we are seeing actually pigment, visible underlying tissue, shadow, swelling — or a combination of several of them?

Until that distinction is made, darkness is only the final appearance.

It is not yet the diagnosis.

The same dark colour can be produced by several different mechanisms

The under-eye region is unusually unforgiving because the skin is thin and the transition between eyelid and cheek contains several structures that can influence colour and shadow.

True melanin-based pigmentation usually produces a brown component. Genetics can contribute, and chronic rubbing, eczema, allergy-related inflammation and ultraviolet exposure may intensify the appearance in susceptible patients.

Vascular or translucent-skin darkness tends to appear more blue, purple or grey because underlying vessels, orbicularis muscle and deeper tissue colour are more visible through thin skin.

Structural darkness behaves differently. A tear trough, midface hollow or lower-eyelid bag changes the way light reaches the under-eye area. The skin itself may have relatively little excess pigment, yet the groove remains dark in ordinary overhead lighting.

These mechanisms can overlap so extensively that colour alone is not enough to classify the problem.

Darkness beneath the eye is often an optical result.

Before I treat the colour, I need to know what is producing the darkness.

Lighting can reveal whether we are looking at colour or shadow

A structural dark circle can change dramatically when the lighting changes.

Overhead light deepens a hollow because the brow and lower-eyelid contour create shadow. More frontal illumination can reduce that shadow and make the region look dramatically brighter without anything in the anatomy actually changing.

This is one reason before-and-after photography around the eyes can be especially misleading.

A subtle change in head position, flash, exposure or light direction can produce an apparent treatment result larger than the anatomical one.

During assessment, I look at the region from several angles and under different light conditions. Gentle manipulation of the surrounding skin and changes in gaze can also help reveal how much of the apparent darkness is caused by contour rather than pigment.

The purpose is not to perform one magical diagnostic test.

It is to stop treating every dark photograph as proof that the skin itself needs lightening.

A tear trough is a contour problem before it is a colour problem

The tear trough is the groove that can develop between the lower eyelid and upper cheek.

Some patients have a visible trough when relatively young because of their inherited anatomy. In others it becomes more apparent over time as orbital, ligamentous and midface soft tissues change.

The depression catches shadow.

This can make the region look dark even when pigmentation is minimal.

When a genuine volume or support deficit is responsible, carefully selected filler or another structural treatment can reduce the depth of the transition and therefore reduce the shadow.

The key point is that the filler has not lightened the skin.

It has changed the geometry that was creating the darkness.

This distinction becomes clinically important if the patient also has true pigment. Correcting the trough can improve the shadow and still leave the brown component visible.

Tear-trough filler is useful precisely because it is not suitable for everyone

The under-eye region has probably suffered more from indiscriminate filler use than from lack of treatment options.

A patient with a clean structural hollow, relatively good skin quality and little tendency to swelling can sometimes obtain a meaningful improvement from a very conservative amount of hyaluronic acid.

A patient with prominent lower-eyelid bags, significant laxity, chronic malar edema or an already full lower-eyelid–cheek junction presents a different problem.

Adding hydrophilic material to tissue that already retains fluid can make the under-eye region look heavier rather than more rested. Likewise, filling below a prominent bag may camouflage a transition to some extent while increasing the total volume of the lower eyelid.

Not every hollow should be filled, and not every shadow is improved by adding volume beneath it.

This is one of the areas where saying no to filler can be more important than knowing how to inject it.

The lower eyelid does not tolerate imprecise volume well

Periorbital skin is thin enough that small contour irregularities can become visible.

Filler placed too superficially or in unsuitable tissue can create persistent puffiness, irregularity or a blue-grey appearance. Delayed edema can occur. Product can remain visible or palpable long after the initial treatment, and previous filler may migrate or alter the contour in ways the patient no longer associates with the old procedure.

These are not theoretical edge cases. Reviews of infraorbital filler complications consistently identify edema, contour irregularity and discoloration among the important problems encountered in this region.

More serious vascular complications are uncommon but possible with facial filler, including rare vision-threatening events.

This gives tear-trough filler a relatively high indication threshold.

If the expected improvement is small, the fact that a syringe can technically be placed there is not enough reason to use it.

Previous under-eye filler can become the cause of today’s under-eye problem

This is something I specifically look for in patients who have been treated before.

The patient may say that their tear trough has returned and assume the filler has completely disappeared because several years have passed.

But filler persistence is variable, and the under-eye region can retain product longer than patients expect.

If residual filler is contributing to edema, a blue-grey hue or an unnatural transition, adding another layer on top does not restore the original anatomy. It compounds an altered one.

In selected cases, ultrasound assessment can help identify existing product. When hyaluronic acid is clearly part of the problem, reduction with hyaluronidase may be more rational than further augmentation.

Revision begins by understanding what remains, not by assuming emptiness.

Under-eye bags and tear troughs can coexist, but they point in opposite directions

A tear trough is a depression.

A lower-eyelid bag is a projection.

They often sit directly beside one another, which is why a bag can make the trough below it look deeper and darker.

Trying to solve the entire picture with filler can become geometrically inefficient. The more prominent the bag, the more surrounding volume is required to camouflage the height difference.

At some point, the lower eyelid simply becomes larger.

When fat prolapse, substantial skin excess or another structural lower-eyelid problem is dominant, blepharoplasty or another surgical discussion may address the anatomy more directly.

This does not mean every eye bag requires surgery.

It means an additive treatment has a limit when the visible problem contains too much projection already.

True pigmentation needs a pigment strategy

If excess melanin is genuinely producing the dark appearance, filler cannot lighten it.

That sounds obvious, yet many patients with pigmented circles have undergone tear-trough treatment because the darkness was interpreted as hollowing.

Pigment management may involve photoprotection, carefully selected topical therapy, treatment of underlying inflammation and, in suitable patients, chemical or energy-based approaches.

The periorbital region requires particular caution because the skin is delicate and inflammation itself can worsen pigmentation.

If a patient has eczema, allergic irritation or a habit of rubbing the eyes, controlling that inflammatory stimulus may be more important than immediately trying to lighten the residual brown colour.

A pigment problem will continue receiving a pigment signal if the inflammation producing it continues.

Allergies and rubbing can be part of the dark-circle mechanism

Some patients have had under-eye darkness for many years and also describe chronic nasal allergy, itchy eyelids or repeated rubbing.

In that setting, inflammation and mechanical irritation can contribute to post-inflammatory pigmentation. Congestion and transient edema can also make the under-eye region look darker or heavier at different times.

This is important because an aesthetic procedure cannot remove an active trigger occurring every day.

If allergy or dermatitis is significant, medical management of that condition belongs earlier in the sequence.

The dark circles may still need cosmetic treatment afterwards.

But the treatment becomes more stable once the tissue is no longer being repeatedly irritated.

Visible vessels and translucent skin create a different limitation

In some patients, the darkness is largely blue or violaceous rather than brown.

The issue may be the visibility of underlying vessels and orbicularis muscle through thin skin.

This is a difficult category because there is not one simple treatment that makes thin eyelid skin thick and opaque.

Selected skin-quality treatments, vascular-targeting approaches or other methods may have a role depending on the specific anatomy and the evidence supporting the proposed treatment.

I would be cautious with claims that one injectable cocktail permanently “improves microcirculation” and solves vascular dark circles. That language often exceeds the clinical evidence.

The objective is usually incremental improvement in skin quality or reduction in the visibility of a defined vascular component, not elimination of everything visible through naturally thin eyelid skin.

Mesotherapy and skin boosters should not become the default answer for every non-filler dark circle

The attraction is understandable.

If the problem is not a tear trough, a superficial injectable treatment feels like the next logical option.

But “skin booster” and “mesotherapy” are broad categories rather than one standardized therapy. Products, ingredients and evidence vary.

A hydration-oriented hyaluronic acid treatment may improve selected aspects of tissue quality without creating structural volume. Other formulations are marketed with claims around vascularity, pigmentation or collagen.

I want those claims judged according to the actual product and the patient’s dominant mechanism.

The fact that the under-eye skin is thin does not mean it automatically benefits from having several biologically attractive ingredients injected into it.

A treatment should still have to explain what it is solving.

Sleep can change the appearance without necessarily being the cause

Dark circles are so strongly associated with tiredness that patients often assume poor sleep created them.

Sleep deprivation can make the region look worse. Fluid balance can change, the skin can look less bright and existing vascular or structural darkness may become more noticeable.

But chronic genetic pigmentation, tear-trough anatomy or thin translucent skin does not disappear permanently after one good night’s sleep.

This distinction matters because it prevents patients from blaming themselves for a feature that is largely anatomical.

It also prevents the opposite mistake of assuming lifestyle is irrelevant.

Temporary aggravating factors can influence appearance without being the primary diagnosis.

Eye creams can help some components, but their limitations should be anatomical rather than dismissive

I would not tell a patient that eye creams are useless because they “only work on the surface”.

Topical products can influence hydration, barrier function and selected pigment pathways. Retinoid or other evidence-based formulations may affect aspects of skin quality when appropriate and tolerated.

What they cannot do is physically fill a tear trough, remove a prominent lower-eyelid fat pad or reposition descended tissue.

This is a much more useful limitation.

Topical treatment is not weak because it is topical. It is simply suited to problems accessible through topical biology.

Anatomical shadow requires an anatomical solution if treatment is needed.

I separate under-eye darkness from under-eye ageing

The two overlap, but they should not be treated as synonyms.

A young person can have genetically dark lower eyelids with excellent skin and no volume loss.

An older patient can develop a deep tear trough, skin laxity and lower-eyelid bags with relatively little pigment.

The first patient may need pigment or skin-focused management, or may decide that no procedure is worth pursuing.

The second may require structural assessment.

If every older-looking under-eye is called a dark circle and every dark circle is called ageing, the treatment categories collapse into one another.

A completely bright under-eye is not a realistic anatomical endpoint

This is one of the expectations I want to address explicitly.

The under-eye area naturally contains transitions, thin skin, vessels, muscle and shadow. It is not supposed to look identical in colour and contour to the central cheek.

Filtered photographs often remove those normal transitions completely.

Trying to reproduce that endpoint can encourage progressive filler, repeated pigment treatment or increasingly aggressive resurfacing.

I want the under-eye to look less tired, not anatomically erased.

For many patients, meaningful improvement means that the dominant trough is softer, the brown component is lighter or the vascular show is less noticeable.

Some residual shadow is compatible with normal anatomy.

Combination treatment is often reasonable because the problem is mixed — but that does not mean everything should be treated at once

A patient can have a tear trough and pigmentation simultaneously.

Another may have thin skin, vascular show and mild swelling.

A mixed mechanism sometimes genuinely requires more than one type of treatment.

I prefer to stage those interventions in an order that makes the diagnostic information clearer.

If the structural shadow is corrected first, we can see how much darkness remains from pigment. If active dermatitis is controlled first, we can judge the residual pigmentation without the inflammatory trigger. If previous filler is reduced, the original anatomy becomes easier to reassess.

This is more useful than performing filler, skin booster and laser in one package and then trying to determine which treatment produced which change.

The plan should become clearer as treatment progresses, not more crowded.

What a good under-eye result means to me

I look for a softer transition between lower eyelid and cheek, less distracting shadow or more even colour depending on the original mechanism.

I do not expect every blue tone to disappear through filler or every hollow to disappear through pigment treatment.

I also do not want the lower eyelid to become visibly fuller simply because a trough once existed beneath it.

The best treatment should make the eyes look less burdened without making the treatment itself obvious.

And because the region is anatomically delicate, sometimes the amount of improvement that can be achieved safely is smaller than the amount of improvement the patient can imagine digitally.

That limitation is part of the consultation, not an excuse after treatment.

When under-eye treatment makes sense to me

I am most comfortable recommending treatment when the dominant mechanism is clear enough that there is a direct relationship between the problem and the proposed intervention.

A structural hollow may justify conservative volume correction. A true pigment problem deserves pigment management. Active inflammatory disease should be stabilised first. Lower-eyelid bags and excess skin may move the discussion toward surgery rather than increasing filler volume.

I become particularly cautious when the patient has chronic edema, substantial previous under-eye filler, very thin tissue, unrealistic expectations of complete brightness or a mixed problem whose components have not yet been separated.

Sometimes no treatment is the more rational choice.

The under-eye region has a narrow margin between correction and visible overcorrection.

For me, that makes diagnosis and restraint more important here than the size of the treatment menu.

Frequently asked questions

What causes dark circles under the eyes?

Common mechanisms include increased pigmentation, visible underlying vessels or muscle through thin skin, structural shadow from tear-trough hollowing or lower-eyelid bags, edema and combinations of these factors. The correct treatment depends on which mechanism dominates.

How can I tell whether my dark circles are pigment or shadow?

Structural shadow often changes substantially with lighting, head position or changes in the eyelid–cheek contour. True pigmentation remains more consistently visible. In practice, many patients have mixed features, so clinical examination is more useful than one home test.

Does tear-trough filler remove dark circles?

It can reduce darkness caused by a structural hollow because it changes the shadow-producing contour. It does not remove melanin or directly treat a vascular colour problem.

Who is not a good candidate for tear-trough filler?

I am particularly cautious in patients with prominent lower-eyelid bags, significant laxity, chronic under-eye or malar edema, unsuitable tissue anatomy or substantial previous filler. In those situations, additional volume can worsen heaviness or swelling.

Can tear-trough filler cause long-term swelling?

Yes. Persistent or delayed edema is a recognised complication of infraorbital filler. This region requires careful product selection, conservative volume and appropriate patient selection.

Can under-eye filler look blue?

A blue-grey discoloration can occur when filler is visible through thin tissue or is placed unfavourably. Previous filler should therefore be considered when evaluating a patient with new or persistent under-eye colour change.

Can old under-eye filler be dissolved?

Hyaluronic-acid filler can often be reduced with hyaluronidase when it is clearly contributing to edema, overcorrection or contour problems. I prefer to establish what product is likely present and what problem it is causing before treating it.

Can eye creams really improve dark circles?

They can help selected components such as hydration, barrier function and some pigment-related concerns. They cannot physically correct a tear trough, remove prominent lower-eyelid bags or change deeper skeletal anatomy.

Can allergies cause dark circles?

Allergic inflammation, rubbing and associated edema can contribute to under-eye pigmentation and darkness in some patients. Controlling the inflammatory trigger can therefore be an important part of treatment.

Does lack of sleep cause permanent dark circles?

Poor sleep can temporarily worsen the appearance, but persistent dark circles often have anatomical, pigmentary or vascular components that are not created solely by sleep deprivation.

Can under-eye bags be treated with filler?

Small adjacent contour differences can sometimes be camouflaged, but significant fat prolapse or skin excess is an additive problem poorly suited to progressively more filler. Surgical lower-eyelid assessment may be more coherent when bags dominate.

Will dark circles disappear completely?

I would not promise complete elimination. Most patients have more than one contributing mechanism, and the lower eyelid naturally contains some degree of shadow and colour variation. The realistic goal is meaningful reduction of the dominant cause while preserving normal anatomy.